← back to search

Thomas Herold

Essen University Hospital ·
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Electric Motor Design and Analysis, and Radiopharmaceutical Chemistry and Applications.
h-index
29
citations
2,541
works
135
NIH funding
primary concept
email

Recent publications

A concurrent, deep learning–based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists
European Radiology 2022cited by 43position: middledoi
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
Journal of Thoracic Oncology 2021cited by 62position: middledoi
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
Clinical Colorectal Cancer 2020cited by 8position: middledoi
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy
Molecular Cancer Therapeutics 2019cited by 32position: middledoi
Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX).
Journal of Clinical Oncology 2018cited by 0position: middledoi
NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma
Oncotarget 2017cited by 85position: middledoi
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients
European Journal of Endocrinology 2016cited by 19position: middledoi
Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST).
Journal of Clinical Oncology 2015cited by 12position: middledoi
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial.
Journal of Clinical Oncology 2015cited by 0position: middledoi
Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients
PLoS ONE 2014cited by 58position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Kurt Werner Schmid · Essen University Hospital6 papers (2014–2020) · 5 papers (2014–2020)Martin Schüler · National Center for Tumor Diseases5 papers (2014–2020) · 4 papers (2015–2020)Stefan Kasper · Heidelberg University3 papers (2014–2020)Susanne Grünewald · Düsseldorf University Hospital2 papers (2015–2019) · 2 papers (2016–2017)Henning Reis · West German Heart and Vascular Center Essen2 papers (2018–2020)W. Berger · Center for Cancer Research2 papers (2015–2020)Sebastian Bauer · TU Dortmund University2 papers (2015–2019) · 2 papers (2015–2020)Frank Breitenbuecher · West German Heart and Vascular Center Essen2 papers (2014–2015)Brigitte Schumacher · Elisabeth-Krankenhaus Essen2 papers (2015–2020) · 2 papers (2015–2020) · 2 papers (2016–2018) · 2 papers (2015–2020)Thomas Mühlenberg · Düsseldorf University Hospital2 papers (2015–2019) · 2 papers (2016–2017) · 2 papers (2015–2020)Julia Ketzer · Essen University Hospital2 papers (2015–2019)